The primary endpoint of AIDS prophylaxis trials is the occurrence of opportunistic infections. While the treatments are not expected to have an effect on the underlying HIV disease, an effect of treatments on mortality cannot be ruled out. Therefore, the primary analysis of these trials must be base
AN OVERVIEW OF STATISTICAL METHODS FOR MULTIPLE FAILURE TIME DATA IN CLINICAL TRIALS
β Scribed by L. J. WEI; DAVID V. GLIDDEN
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 194 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0277-6715
No coin nor oath required. For personal study only.
β¦ Synopsis
In a long term clinical trial to evaluate a new treatment, quite often each study subject may experience a number of 'failures' that correspond to repeated occurrences of the same type of event or events of entirely different natures during his/her follow-up period. To obtain efficient inference procedures for the therapeutic effect over time, it is desirable to utilize those multiple event times in the analysis. In this article, we review some useful procedures for analysing different kinds of multivariate failure time data. Specifically, we discuss the two-sample problems and the general regression problems with various survival models. We also give some recommendations of appropriate procedures for each type of multiple event data structure for practical usage.
π SIMILAR VOLUMES
We consider multivariate tests for comparing two treatments with multiple endpoints. The test decision is drawn from the simultaneous consideration of the univariate tests for the single endpoints. A general class of these tests, called cut-o! tests, can be given, which, however, can lead to highly
have presented recently an interesting paper on the way to analyse AIDS clinical trials when we have a combined endpoint of infection recurrences and death. They use one of the most famous multivariate generalizations of the proportional hazards model: the model of Wei, Lin and Weissfield (hereafter
This paper considers five methods of analysis of longitudinal assessment of health related quality of life (QOL) in two clinical trials of cancer therapy. The primary difference in the two trials is the proportion of participants who experience disease progression or death during the period of QOL a
The principal response criteria for many clinical trials involve time-to-event variables. Usual methods of analysis for this type of response criterion include product-limit estimators of cumulative survival for the treatment groups, (stratified) logrank tests to compare treatments, and proportional